Increased levels of legumain in plasma and plaques from patients with carotid atherosclerosis
- PMID: 27940038
- DOI: 10.1016/j.atherosclerosis.2016.11.026
Increased levels of legumain in plasma and plaques from patients with carotid atherosclerosis
Abstract
Background and aims: The cysteine protease legumain has been shown to be up-regulated in unstable atherosclerotic plaques. This study aims to further elucidate legumain in atherosclerosis, by examining legumain in plasma and carotid plaques from patients with carotid stenosis. Furthermore, legumain secretion from monocyte-derived macrophages treated with atherogenic lipids during macrophage polarization was studied.
Methods: Plasma levels of legumain from patients with carotid stenosis (n = 254), healthy controls (n = 91), and secreted from monocyte-derived macrophages were assessed by enzyme-linked-immunosorbent assay. Quantitative PCR and immunoblotting of legumain were performed on isolated plaques and legumain localization was visualized by immunohistochemistry and fluorescence microscopy. Monocyte-derived macrophages polarized to M1 or M2 macrophages were treated with VLDL, oxLDL or cholesterol crystals (CC) and the level of legumain analysed.
Results: Patients with carotid stenosis had significantly higher levels of plasma legumain compared with healthy controls (median 2.0 versus 1.5 ng/ml, respectively; p = 0.003), although there was no correlation between the level of legumain and the degree of stenosis, and legumain was not an independent factor to identify patients with carotid plaques. Moreover, patients with symptoms the last 2 months had higher expressions of mature legumain, cystatin C and E/M, and the macrophage markers CD80 (M1) and CD163 (M2). Legumain co-localized with both M1 and M2 macrophages within plaques, whereas legumain mRNA expression was significantly higher (p < 0.0001) in plaques compared to non-atherosclerotic arteries (controls). Furthermore, in vitro studies showed significantly increased secretion of legumain from pro-inflammatory M1 compared to pro-resolving M2 macrophages (p = 0.014), and particularly in M1 treated with CC. In plaques, legumain was localized to structures resembling foam cells.
Conclusions: Legumain is increased in both plasma and plaques of patients with carotid stenosis and might be a new and early biomarker of atherosclerosis.
Keywords: Asparaginyl endopeptidase (AEP); Atherosclerosis; Carotid; Cholesterol crystals; Cystatins; Inflammation; Legumain; Macrophage polarization; Plaque; Proteases.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Comment in
-
Clinical relevance of biomarkers for the identification of patients with carotid atherosclerotic plaque: Potential role and limitations of cysteine protease legumain.Atherosclerosis. 2017 Feb;257:248-249. doi: 10.1016/j.atherosclerosis.2017.01.003. Epub 2017 Jan 18. Atherosclerosis. 2017. PMID: 28126320 No abstract available.
Similar articles
-
Role of legumain in metabolic dysfunction, diagnosis, and prognosis of patients with atherosclerosis.Medicine (Baltimore). 2024 Jul 19;103(29):e38896. doi: 10.1097/MD.0000000000038896. Medicine (Baltimore). 2024. PMID: 39029045 Free PMC article.
-
Increased expression of TFPI in human carotid stenosis.Thromb Res. 2017 Jul;155:31-37. doi: 10.1016/j.thromres.2017.04.024. Epub 2017 Apr 28. Thromb Res. 2017. PMID: 28482260
-
Legumain suppresses OxLDL-induced macrophage apoptosis through enhancement of the autophagy pathway.Gene. 2018 Apr 30;652:16-24. doi: 10.1016/j.gene.2018.02.012. Epub 2018 Feb 4. Gene. 2018. PMID: 29414692
-
Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy.Heart Fail Rev. 2019 May;24(3):399-409. doi: 10.1007/s10741-018-09764-z. Heart Fail Rev. 2019. PMID: 30673930 Review.
-
Macrophage phenotypic plasticity in atherosclerosis: The associated features and the peculiarities of the expression of inflammatory genes.Int J Cardiol. 2015 Apr 1;184:436-445. doi: 10.1016/j.ijcard.2015.03.055. Epub 2015 Mar 5. Int J Cardiol. 2015. Retraction in: Int J Cardiol. 2021 Feb 15;325:186. doi: 10.1016/j.ijcard.2020.12.067. PMID: 25755062 Retracted. Review.
Cited by
-
Legumain in cardiovascular diseases.Exp Biol Med (Maywood). 2024 Jul 22;249:10121. doi: 10.3389/ebm.2024.10121. eCollection 2024. Exp Biol Med (Maywood). 2024. PMID: 39104790 Free PMC article. Review.
-
Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis.Stem Cell Reports. 2017 Feb 14;8(2):373-386. doi: 10.1016/j.stemcr.2017.01.003. Epub 2017 Feb 2. Stem Cell Reports. 2017. PMID: 28162997 Free PMC article.
-
Trichomonas vaginalis Legumain-2, TvLEGU-2, Is an Immunogenic Cysteine Peptidase Expressed during Trichomonal Infection.Pathogens. 2024 Jan 27;13(2):119. doi: 10.3390/pathogens13020119. Pathogens. 2024. PMID: 38392857 Free PMC article.
-
Activating FcγRs on monocytes are necessary for optimal Mayaro virus clearance.bioRxiv [Preprint]. 2024 Jul 24:2024.07.23.604823. doi: 10.1101/2024.07.23.604823. bioRxiv. 2024. PMID: 39149309 Free PMC article. Preprint.
-
Plasma proteomics and carotid intima-media thickness in the UK biobank cohort.Front Cardiovasc Med. 2024 Oct 2;11:1478600. doi: 10.3389/fcvm.2024.1478600. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39416432 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials